Amato R J
Department of Genitourinary Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Semin Oncol. 2000 Apr;27(2):177-86.
Renal cell carcinoma is highly resistant to systemic chemotherapy, and no agent should be considered standard in the treatment of metastatic disease. At this time, it is appropriate for patients with advanced local or metastatic renal cell carcinoma to be offered new therapeutic investigational experimental options, since clearly there are limited therapies presently available. The experience with chemotherapy is reviewed.
肾细胞癌对全身化疗具有高度耐药性，在转移性疾病的治疗中，尚无任何药物可被视为标准治疗药物。目前，对于晚期局部或转移性肾细胞癌患者，提供新的治疗性研究实验选择是合适的，因为目前可用的治疗方法显然有限。本文对化疗的经验进行了综述。
